What's Happening?
Perceptive Discovery, a preclinical CRO specializing in radiopharmaceutical and oncology drug development, has announced a strategic collaboration with Certis Oncology, a company focused on precision oncology and translational science. This partnership
aims to integrate Certis Oncology's patient-derived models with Perceptive Discovery's capabilities in radiochemistry and imaging to support comprehensive radiopharmaceutical development. The collaboration will provide sponsors with enhanced strategies for evaluating targeted radiotherapeutics and radiotracers, utilizing clinically characterized models to improve translational insight and biological context. This initiative is expected to advance the U.S. radiopharmaceutical market by offering more integrated and biologically relevant approaches to drug development.
Why It's Important?
The collaboration between Perceptive Discovery and Certis Oncology is significant as it addresses the growing complexity and data-rich nature of oncology development. By combining expertise in translational oncology and radiochemistry, the partnership aims to generate decision-ready preclinical datasets that can reduce risk and accelerate the development of radiopharmaceutical therapies. This is particularly important as the demand for targeted cancer treatments increases, necessitating more sophisticated preclinical approaches. The collaboration is poised to enhance the U.S. radiopharmaceutical market by providing more comprehensive and biologically relevant evaluation methods, potentially leading to more effective cancer treatments and improved patient outcomes.
